NYSE:AMWL - New York Stock Exchange, Inc. - US03044L2043 - Common Stock - Currency: USD
American Well (AMWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 46.5% upside potential for American Well (AMWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here is how American Well Corporation (AMWL) and Claritev Corporation (CTEV) have performed compared to their sector so far this year.
Mentions: CTEV
Amwell Announces Results for First Quarter 2025...
The headline numbers for American Well (AMWL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
American Well (AMWL) delivered earnings and revenue surprises of 44.01% and 11.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: OM
Amwell to participate in upcoming investor conferences...
Amwell to report first quarter 2025 operating results...
Amwell announces innovation leader as chief product and technology officer...
Amazon veteran Dan Zamansky joins company’s executive team
Amwell Makes Grants to New Employees Under Inducement Plan...
Amwell® to participate in upcoming investor conference...
AMWL earnings call for the period ending December 31, 2024.
Amwell® Announces Results for Fourth Quarter and Full Year 2024...
Amwell CFO Mark Hirschhorn Expands Leadership Role; assumes responsibility for operations and sales as COO ...
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock...
Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care....
Vida to offer cardiometabolic solutions including GLP-1s and other anti-obesity medications on the Amwell platform
Amwell divests virtual psychiatric care business to Avel eCare in all-cash transaction...